Why the study?
DOACs are associated with higher gastrointestinal bleeding risks that may differ by sex, but females were underrepresented in DOAC pivotal trials.
Does female gender increase the risk of gastrointestinal bleeding in patients ≥65 years with atrial fibrillation treated with oral anticoagulants?
Does female gender increase the risk of gastrointestinal bleeding in patients ≥65 years with atrial fibrillation treated with oral anticoagulants?
In older patients with atrial fibrillation, female gender is associated with a significantly higher risk of gastrointestinal bleeding when treated with DOACs, a disparity not seen with VKAs.
Female sex associated with higher GI bleeding on DOACs in older AF; hypothesis-generating, requires prospective confirmation before practice change.
Background: DOACs are characterized by a higher incidence of gastrointestinal bleeding and this may be different among males and females. Female patients were underrepresented in the DOAC pivotal trials. We aimed to assess real-world differences in gastrointestinal bleeding with oral anticoagulants (DOACs and VKAs) among males and females with atrial fibrillation. Methods: We performed a population-based retrospective analysis on linked administrative claims. Atrial fibrillation patients of 65 years and above were considered. Bleeding risk factors were assessed through HASBED and previous history of gastrointestinal disease. A time-to-event analysis compared gastrointestinal bleeding between males and females. Results: The overall cohort consisted of 15338 (55% female) DOAC and 44542 (50% female) VKA users. Most of the patients showed HASBED ≥2. Incidence rate of GI bleeding was higher in females as compared to males among DOAC users (0.90% vs 0.59%), and significant gender difference in GI bleeding was found, after adjustment, in the Cox regression analysis (HR 1.48, 95%CI 1.02-2.16). In the VKA group, no significant difference among genders was found in the time-to-event analysis. Conclusions: Our data suggest that female patients treated with DOACs have a higher risk of GI bleeding versus male patients; this difference is not observed in VKA patients.
No takes yet. Share an insight, caveat, or question.
Ferroni et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: